Search company, investor...

Founded Year



Seed VC | Alive

Total Raised


Last Raised

$6M | 1 yr ago

About emma

emma provides management services and data transmission solutions to deliver cloud services directly to end customers and partners. It offers a cloud management no-code platform that simplifies the deployment, management, and scaling of clusters, applications, and virtual machines. It was founded in 2019 and is based in Luxembourg City, Luxembourg.

Headquarters Location

9, Rue du Laboratoire

Luxembourg City, 1911,




Expert Collections containing emma

Expert Collections are analyst-curated lists that highlight the companies you need to know in the most important technology spaces.

emma is included in 1 Expert Collection, including Artificial Intelligence.


Artificial Intelligence

11,383 items

Companies developing artificial intelligence solutions, including cross-industry applications, industry-specific products, and AI infrastructure solutions.

Latest emma News

The International Myeloma Foundation Welcomes Global Leader & Patient Advocate Emma Hatcher as Global VP of Patient Engagement & Advocacy

Aug 31, 2023

Prior to joining the IMF, Hatcher worked as the Global Head of Patient Affairs at Grifols—a global healthcare company that provides innovative healthcare services and solutions in over 100 countries. As the Global Head of Patient Affairs at Grifols, Hatcher established a progressive vision; a new value proposition for rare disease patients; and a new focus on global collaboration to elevate patient insights to improve the patient and caregiver experience. In that role, Hatcher renewed the company’s approach to patient engagement with a clear focus on partnering with company leadership across Medical Affairs, Global Marketing, Market Access, and R&D to deliver insights that improve the patient experience. “I am honored to join the IMF and have the opportunity to further their critical mission. Joining the IMF’s dedicated team to partner with the myeloma community feels like the culmination of my career spent working to co-develop positive health outcomes,” said Hatcher about being chosen for the role. “My time in industry has allowed me to see the impact of healthcare on a global scale firsthand and the immense potential of embedding the patient voice into strategy and decision-making. That experience provided me insights into a wide spectrum of healthcare challenges—from developing innovative treatments and improving existing treatments, to enhancing patient access to medicines.” For Hatcher, the commitment to elevating patient voice is not only a professional passion but also the result of personal struggle. “I have walked the arduous journey of a rare disease diagnosis with my mother. Through this experience, I have seen the impact that a patient-focused nonprofit has in providing unbiased, clear information; profound support; and a sense of hope and community. The IMF's impact on the myeloma community and its focus on a rare disease is inspiring. I am genuinely moved by the chance to be part of an organization that is singularly focused on improving the lives of those affected by multiple myeloma.” As an experienced strategy, patient advocacy, and policy professional who has had over 20 years of experience in the healthcare industry, Hatcher hopes to bring her fresh perspective and knowledge to the IMF team by engaging the IMF’s vast myeloma-impacted community in identifying and advocating for healthcare solutions. “I want to thank the IMF leadership for the opportunity to bring my passion for patient advocacy to this role. Today, I look forward to meeting members of the community—to listen and learn about their experiences and journeys. Tomorrow, I look forward to being an informed, compassionate, and effective advocate for the priorities of the community,” she further expressed. "At the IMF, our primary focus has always been doing what's best for individuals diagnosed with myeloma. As we accelerate our journey of transformation, in addition to advocating and speaking for the people we serve, we will help the people we serve get heard," said IMF President & CEO and 28-year myeloma survivor Yelak Biru. “With Emma's appointment as Global VP of Patient Engagement and Policy, the IMF will take steps to enhance our organizational capabilities, platforms, and forums to enable individuals diagnosed with myeloma to actively express their wants and needs. The IMF has a large network of myeloma patients—we are uniquely positioned to create this model.” “Emma’s leadership, passion, personal experience, and capabilities for engagement will allow us to build a new model of service under one global team. I look forward to working with Emma and advancing our patient engagement and advocacy agenda," said Yelak in closing. Biography Hatcher is an experienced strategist and policy leader who brings over 20 years of experience in organizational leadership and patient advocacy. She is a proven leader with extensive international experience within a complex, highly regulated, multi-national environment. Hatcher earned a Master’s degree in Public Health with a Focus in Policy from Brown University and a Bachelor of Sciences from the University of Rhode Island. Emma resides in the Washington D.C. area. ABOUT MULTIPLE MYELOMA Multiple myeloma is a cancer of the bone marrow plasma cells — white blood cells that make antibodies. A cancerous or malignant plasma cell is called a myeloma cell. Myeloma is called “multiple” because there are frequently multiple patches or areas in bone where it grows. It can appear as both a tumor and/or an area of bone loss, and it affects the places where bone marrow is active in an adult: the hollow area within the bones of the spine, skull, pelvis, rib cage, and the areas around the shoulders and hips. ABOUT THE INTERNATIONAL MYELOMA FOUNDATION Founded in 1990, the International Myeloma Foundation (IMF) is the first and largest global foundation focusing specifically on multiple myeloma. The Foundation’s reach extends to more than 525,000 members in 140 countries worldwide. The IMF is dedicated to improving the quality of life of myeloma patients while working toward prevention and a cure by focusing on four key areas: research, education, support, and advocacy. The IMF has conducted more than 250 educational seminars worldwide, maintains a world-renowned InfoLine, and in 2001, established the International Myeloma Working Group (IMWG), a collaborative research initiative focused on improving myeloma treatment options for patients. In 2012, the IMF launched the Black Swan Research Initiative®, a groundbreaking research project aimed at curing myeloma. The IMF can be reached at (800) 452-CURE (2873). The global website is . Follow the IMF on:

emma Frequently Asked Questions (FAQ)

  • When was emma founded?

    emma was founded in 2019.

  • Where is emma's headquarters?

    emma's headquarters is located at 9, Rue du Laboratoire, Luxembourg City.

  • What is emma's latest funding round?

    emma's latest funding round is Seed VC.

  • How much did emma raise?

    emma raised a total of $6.05M.

  • Who are the investors of emma?

    Investors of emma include AltaIR Capital, CircleRock Capital, RTP Global and Fit 4 Start.

  • Who are emma's competitors?

    Competitors of emma include Kubeark.


Compare emma to Competitors

Kubeark Logo

Kubeark provides software to implement cloud strategies and helps to control workloads and data management. The company offers an application that is used by vendors to deploy, manage, and scale their tasks. Kubeark was founded in 2022 and is based in Manhasset, New York.


ControlMonkey develops a cloud operations platform. The company offers services to enable DevOps leaders to manage their cloud infrastructure proactively, initiating terraform to automate and govern cloud environments. It provides the tools and processes to amplify Infrastructure as Code (IaC) benefits to gain full governance on the cloud and prevent service interruptions, misconfigurations, and non-compliant resources. Its primary customers are within the cloud computing industry. It was founded in 2022 and is based in Tel Aviv, Israel.

nOps Logo

nOps is an artificial intelligence (AI)-powered software as a service (SaaS) service. It assists businesses in constructing, managing, and operating a secure and operational AWS or Azure infrastructure. It enables managed service providers (MSPs) to rethink cloud management by enhancing productivity and the ability to identify and resolve high-risk issues for customers, as well as provide value-added services for cost, security, and risk management that help clients achieve and maintain well-architected environments. It was founded in 2017 and is based in San Francisco, California.


Ankra operates as a cloud infrastructure automation platform. It provides automation and integration for software companies and enables development efficiency, reduces costs as well as significantly bolster security and insight into the cloud infrastructure, thus provisioning and empowering developers to focus on their application code. The company was founded in 2021 and is based in Stockholm, Sweden.

Cloud Accel

Cloud Accel is a company that focuses on IT modernization within the technology sector. The company offers services such as cloud migration, IT optimization, disaster recovery, and IT infrastructure monitoring. It primarily serves businesses in need of IT infrastructure solutions. It was founded in 2017 and is based in Boca Raton, Florida.

LeanIX Logo

LeanIX offers a software-as-a-service web-based platform for enterprise architecture management (EAM). Its solutions include application portfolio assessment and application rationalization, obsolescence risk management, application modernization and cloud migration, and more. The company was founded in 2012 and is based in Bonn, Germany. In September 2023, LeanIX was acquired by SAP. The terms of the transaction were not disclosed.


CBI websites generally use certain cookies to enable better interactions with our sites and services. Use of these cookies, which may be stored on your device, permits us to improve and customize your experience. You can read more about your cookie choices at our privacy policy here. By continuing to use this site you are consenting to these choices.